Acturadar.comFrance in real time

English translation in progress — this text is still shown in French.

Anti-obesity drugs in France: controls, reimbursement and off-label uses

Ongoing24 events · of the 28 Oct au 18 Nov · latest fact at 21h15

View entire story

Fact 23 of 24 in the story · Wednesday 18 November, 14h30

Des patients témoignent de leur traitement anti-obésité

Des patients en France métropolitaine et à Saint-Pierre-et-Miquelon racontent leur quotidien sous traitement anti-obésité. L'article rapporte des prescriptions croissantes d'Ozempic, Wegovy et Mounjaro et des témoignages de confiance retrouvée.

In brief

Health event (severity: low) nationwide, first detected on 18 November 2026 at 14:30. Reported by 1 source (1 article), last updated on 18 November 2026 at 14:30. Part of the story “Anti-obesity drugs in France: controls, reimbursement and off-label uses”.

·
Category
Health
Severity
Low
Place

National

Detected
18 Nov, 14h30
Updated
18 Nov, 14h30
Reference
no.24194
01

What changed in the story at that point

02

Who is covering it, and from what angle

Method
1Uncategorised

1 article · 1 source · no rated outlet covers this topic yet (public service, agencies, official accounts…)

Story angles

This event does not yet have its own comparison: here is the story's Anti-obesity drugs in France: controls, reimbursement and off-label uses.

The three sides cover the same issue (the arrival of oral Wegovy, French enthusiasm, risks and trafficking), but differ in angle: the left prioritizes testimonies and individual health risks, the center extensively covers the Ifop poll and practical alerts, the right highlights the market explosion, side effects and economic and regulatory aspects.

Left

Highlights personal testimonies (a patient who lost weight without medication, a formerly obese person warning about Wegovy), health risks linked to off-label use and recourse to parallel markets, as well as changes in eating habits.

Centre

Extensively covers the Ifop poll (one in five French people tempted, even without being obese), health professionals' alerts on injections and harmful substances, influencers diverting medications, and customs controls against trafficking.

Right

Highlights the explosion of the appetite suppressant market and the multiplication of side effects, the non-reimbursable nature of oral Wegovy, consultation waiting times and the economic aspects of treatment.

Common points

  • =Wegovy is now available in tablet form in France since early November
  • =Around one in five French people consider using GLP-1s to lose weight according to the Ifop survey
  • =Health professionals and authorities warn about risks and side effects
  • =Off-label uses and illegal purchases or parallel markets are reported

Divergences

  • ≠The left insists on weight-loss testimonies without medication and individual warnings, an angle little present in the center and on the right
  • ≠The right highlights the market explosion, side effects and economic impact, more than the left
  • ≠The center develops influencer cases and customs trafficking as a main angle, less central on the left and right

Written by an AI from headlines and extracts only of all events in the story · 14 Nov, 15h44

03

Lire les sources · 1 article, 1 source

Publication order
  1. 14h30
    La 1ère (Outre-mer)Report18 Nov
    "Je revis" : Ozempic, Wegovi, Mounjaro...sous traitement contre l’obésité, ils retrouvent confiance en eux

    À Saint-Pierre-et-Miquelon tout comme en France métropolitaine, les prescriptions de traitement anti-obésité sont de plus en plus fréquentes. Des patients racontent leur nouveau quotidien.

04

Further reading